Using cancer-related diagnosis at an early stage and respond to changes in a targeted manner
We develop innovative bioanalytical methods to sensitively detect and precisely characterize DNA sequences and proteins from cancer cells.
Cancer-related diagnostics (e.g., MRD monitoring) is able to diagnose changes in the residual cancer burden at the molecular level at an early stage for many cancers. To this end, we develop innovative bioanalytical methods to sensitively detect and precisely characterize DNA sequences and proteins from cancer cells. The biochemical analytical methods are standardized, miniaturized, and automated using our lab-on-a-chip platforms, which make high-quality analytics available on a decentralized basis.
We use a wide range of different technologies to provide personalized cancer diagnostics. We use personalized multiplex real-time PCR systems to monitor multiple targets in parallel in the same patient. By using the mediator probe PCR and clearly defined guidelines, we are able to quickly adapt these test systems to different patient-specific DNA sequences. Thanks to our LabDisk platform, we have been able to demonstrate that personalized multiplex real-time PCR can be automated.
Furthermore, we develop microfluidic procedures to automate the preparation of an NGS library. This technology combines the digital amplification of nucleic acids with the labeling of DNA sequences via a unique molecular identifier. The goal is to make the NGS quantification of cancer cells more efficient and less prone to error.
Our technology helps to capture the dynamic processes of cancers
The development of multi-omega immunoassays also makes it possible to use proteins, protein interactions, and biological signaling pathways to assess patient status. As a result, the complex processes that are involved in cancer formation and development can be detected early, and new types of markers can be identified.
A key to the development of personalized diagnostics is the combination of different technological areas. This includes the development of molecular biological assays and microfluidic platforms as well as user-friendly software that makes it easier for users to deploy increasingly complex analytics in practice. We would be happy to apply our expertise to your project and look forward to hearing from you.